NCT07430332Not yet recruitingPhase 2
GLP-1 RA for Stage 1 Type 1 Diabetes
Leveraging Semaglutide for Preservation of Beta Cell Function and Restoration of Alpha Cell Function
Source: ClinicalTrials.gov · Last updated 24 Feb 2026
Brief summary (registry, in English)
This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes. The goal of this study is to see if semaglutide can protect beta cell function in this group of people and delay the progression to stage 2 type 1 diabetes.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 18 Feb 2026
- Start date
- 1 Sept 2027
- Primary completion date
- 1 Jun 2029
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Diseases
- Type 1 diabetes
- NCT number
- NCT07430332
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 15
- From 1 Sept 2027 to the primary completion date, 1 Jun 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of anaphylaxis or allergies to GLP-1 receptor agonists
- History of bariatric surgery
- Personal or family history of cancer such as medullary thyroid cancer
- Personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis
Other
- Already on a GLP-1 receptor agonist
- Severe hypoglycemia within 3 months of study enrollment
- Pregnant, breastfeeding, or the intention of becoming pregnant or not using adequate contraceptive measures
- Adult individuals with BMI \< 18.5 kg/m2 and pediatric participants with BMI \< 5th percentile
Who the study is looking for
- Stage 1 Type 1 Diabetes
- Screening OGTT with impaired or loss of first phase insulin secretion but no dysglycemia to suggest stage 2 or stage 3 type 1 diabetes
Age in the registry: 12 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cincinnati Children's Hospital Medical Center Coordinator of this site? Confirm its status | Cincinnati | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.